Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
UK Drug Safety Update · June 16, 2026
ACE-inhibitors: distinction between bradykinin- and histamine-mediated angioedema and treatment strategies
Original title: ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly
Healthcare professionals advised to distinguish bradykinin- from histamine-mediated angioedema in ACE-inhibitor use, as treatment strategies differ significantly.
Published by UK Drug Safety Update. HealthSignal links to the original document; the summary above is extracted from the source text.